LIFE - aTyr Pharma, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
4.00
+0.10 (+2.56%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close3.90
Open3.90
Bid2.35 x 100
Ask0.00 x 0
Day's Range3.80 - 4.05
52 Week Range2.10 - 6.50
Volume36,243
Avg. Volume104,650
Market Cap119.033M
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Associated Press25 days ago

    Atyr Pharma reports 3Q loss

    The San Diego-based company said it had a loss of 43 cents per share. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for ...

  • Zacks.com featured highlights include article Kraton, aTyr Pharma, Grupo Financiero Galicia, Grupo Supervielle and Calithera Biosciences
    Zacks2 months ago

    Zacks.com featured highlights include article Kraton, aTyr Pharma, Grupo Financiero Galicia, Grupo Supervielle and Calithera Biosciences

    Zacks.com featured highlights include article Kraton, aTyr Pharma, Grupo Financiero Galicia, Grupo Supervielle and Calithera Biosciences

  • How Should You Think About aTyr Pharma Inc’s (LIFE) Risks?
    Simply Wall St.2 months ago

    How Should You Think About aTyr Pharma Inc’s (LIFE) Risks?

    For aTyr Pharma Inc’s (NASDAQ:LIFE) shareholders, and also potential investors in the stock, understanding how the stock’s risk and return characteristics can impact your portfolio is important. The beta measuresRead More...

  • Associated Press4 months ago

    Atyr Pharma reports 2Q loss

    On a per-share basis, the San Diego-based company said it had a loss of 51 cents. In the final minutes of trading on Monday, the company's shares hit $3.25. A year ago, they were trading at $3.42. _____ ...

  • Associated Press7 months ago

    Atyr Pharma reports 1Q loss

    The San Diego-based company said it had a loss of 56 cents per share. In the final minutes of trading on Thursday, the company's shares hit $3.10. A year ago, they were trading at $3.01. _____ This story ...

  • Associated Press9 months ago

    Atyr Pharma reports 4Q loss

    On a per-share basis, the San Diego-based company said it had a loss of 53 cents. For the year, the company reported a loss of $57.9 million, or $2.44 per share. In the final minutes of trading on Thursday, ...

  • Investopedia9 months ago

    aTyr Pharma Rises 16% on Orphan Drug Status

    Atyr Pharma was granted orphan drug status for its Resolaris muscular dystrophy drug.

  • Associated Press10 months ago

    High court ruling limits international reach of patent laws

    WASHINGTON (AP) — The Supreme Court on Wednesday sided with California-based Life Technologies Corp. in a patent infringement case that limits the international reach of U.S. patent laws.

  • Investopedia11 months ago

    Atyr Pharma Stock Spikes 33% on FDA Updates

    Atyr Pharma said the FDA gave its Resolaris drug fast-track status and lifted a partial hold on a study.

  • Associated Press11 months ago

    Roberts recuses from patent case after discovering conflict

    Supreme Court Chief Justice John Roberts says he will no longer participate in deciding a patent infringement case because he discovered he owns shares in the parent company of one of the parties. Roberts ...

  • GuruFocus.comlast year

    Atyr Pharma Inc (LIFE) CEO and Director John Mendlein Bought $151,800 of Shares

    CEO and Director of Atyr Pharma Inc (NASDAQ:LIFE) John Mendlein bought 69,000 shares of LIFE on 12/19/2016 at an average price of $2.2 a share.

  • Does aTyr Pharma Inc (LIFE) Stack Up Against Its Peers?
    Insider Monkeylast year

    Does aTyr Pharma Inc (LIFE) Stack Up Against Its Peers?

    A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors can look at the overall hedge fund sentiment towards the stocks included in their watchlists. These freshly-submitted public filings disclose money managers’ equity positions as of the end of the three-month period […]

  • 24/7 Wall St.last year

    aTyr Pharma Drops on Clinical Update

    aTyr Pharma shares dropped early on Tuesday after the company announced clinical results from its exploratory trials assessing the safety and potential activity of Resolaris.